Related by context. All words. (Click for frequent words.) 78 reach statistical significance 65 achieved statistical significance 62 noninferiority 62 statistical significance 62 attain statistical significance 60 primary endpoint 60 ABC/3TC 59 secondary endpoints 59 non inferiority 59 active comparator 59 FOLFOX4 59 secondary efficacy endpoints 59 prespecified 58 morphometric vertebral fractures 58 secondary endpoint 58 ticagrelor 58 elagolix 58 antipsychotic efficacy 58 statistically significant 58 efficacy endpoints 58 cangrelor 58 primary endpoints 57 primary efficacy endpoints 57 statistically significant p = 57 prospectively defined 57 NEVO ™ 57 subgroup analyzes 57 iniparib 57 bosutinib 57 statistical significance p 57 tapentadol ER 56 clinical endpoints 56 TDF FTC 56 ALVESCO 56 comparator arm 56 rolofylline 56 #mg QD [001] 56 irbesartan 56 primary efficacy endpoint 55 #mg dose [003] 55 placebo p 55 ATACAND 55 lumbar spine BMD 55 eptifibatide 55 valopicitabine 55 nonrandomized 55 abatacept 55 maximally tolerated dose 55 ZOLINZA 55 abciximab 55 unfractionated heparin 55 febuxostat 55 statistically significant superiority 55 Ereska 55 achieve sustained virologic 55 statistically significant improvement 55 nonresponders 55 oxycodone CR 55 carvedilol 55 bicifadine 55 virologic failure 55 FOLFOX 55 peginterferon alfa 2b 55 HCV RESPOND 2 55 sunitinib 54 5-FU/LV 54 efficacy endpoint 54 LPV r 54 TELCYTA 54 clinically meaningful 54 interferon gamma 1b 54 SVR# 54 Free Survival PFS 54 apremilast 54 FOLFIRI 54 confirmatory clinical 54 sustained virologic response 54 #.#/#.# mmHg [001] 54 placebo p = 54 secondary efficacy endpoint 54 infarct size 54 nonsignificant 54 ARB telmisartan 54 pharmacokinetic equivalence 54 everolimus eluting stents 54 XGEVA 54 composite endpoint 54 Palifosfamide 54 levosimendan 54 cabazitaxel 54 noninferior 54 tirofiban 54 clazosentan 54 mcg QD 54 mg dose 54 paclitaxel eluting stents 54 bezafibrate 54 statistically significant differences 54 aflibercept 54 placebo 54 pioglitazone 54 pegylated interferon alfa 2b 54 bivalirudin 54 plus dexamethasone 54 clodronate 53 CIMZIA TM 53 ALLHAT 53 cisplatin vinorelbine 53 ADAS Cog 53 ACUITY trial 53 tecarfarin 53 QTc 53 methotrexate monotherapy 53 LVEF 53 demonstrated statistically significant 53 PASI scores 53 AEGR 53 tolvaptan 53 Phenoptin 53 adefovir 53 Xalatan R 53 median PFS 53 etanercept 53 mapatumumab 53 viral kinetics 53 GSK# [001] 53 mycophenolic acid 53 XIENCE V PROMUS Stent 53 IIIa inhibitor 53 nicardipine 53 XELOX 53 ACTEMRA TM 53 DMARD 53 4mg/kg 53 desvenlafaxine succinate 53 limiting toxicity 53 R# #mg BID 53 CIMZIA ™ 53 sirolimus eluting stents 53 elotuzumab 53 mg kg dose 53 plus prednisone 53 locoregional recurrence 53 intravesical therapy 53 fosbretabulin 53 valsartan 53 splenectomized patients 53 interferon alfa 53 sirolimus eluting stent 53 periprocedural 53 Kaplan Meier analysis 53 #mg BID [001] 53 Tarceva TM 53 pertuzumab 53 raltegravir 53 Taxus Stent 53 baseline HbA1c 53 carboplatin paclitaxel 53 plus ribavirin 52 VIRAMUNE 52 Azixa 52 genotypic resistance 52 CIMZIA TM certolizumab pegol 52 cediranib 52 fondaparinux 52 gefitinib 52 binary restenosis 52 tiotropium 52 subanalysis 52 cilostazol 52 Doxil ® 52 erlotinib 52 BENICAR HCT 52 dacetuzumab 52 ADAS cog 52 ribavirin RBV 52 apolipoprotein B 52 alvimopan 52 pCR 52 STRIDE PD 52 endometrial thickness 52 eplerenone 52 abacavir lamivudine 52 CoFactor 52 alteplase 52 bosentan 52 pegylated interferon peg IFN 52 fluoropyrimidine 52 Thal Dex 52 IOP lowering 52 mCRC patients 52 achieved ACR# 52 lispro 52 TNF inhibitor 52 vandetanib 52 NATRECOR ® 52 insulin glargine 52 endoscopic remission 52 pegaptanib 52 MAGE A3 ASCI 52 APOPTONE 52 nab paclitaxel 52 clinically relevant 52 lopinavir r arm 52 XIENCE V demonstrated 52 MACCE 52 TLUS 52 Elitek 52 sorafenib 52 relapsers 52 teriflunomide 52 placebo controlled clinical 52 Aptivus ® 52 APPRAISE 52 tipranavir r 52 highly emetogenic 52 virologic response 52 decitabine 52 pegylated interferon 52 insulin detemir 52 statistically significant reduction 52 ketorolac 52 anastrozole 52 sorafenib Nexavar 52 tipranavir 52 interferon alfa 2b 52 LEVADEX 52 bevacizumab 52 azacitidine 52 Xelox 52 neurologic progression 52 trastuzumab 52 EDEMA3 trial 52 progression TTP 52 IFN alfa 52 Vectibix 52 serum urate 51 CI -#.# 51 lintuzumab 51 adjuvant colon cancer 51 imatinib therapy 51 peginterferon 51 mITT 51 pexelizumab 51 OADs 51 CINQUIL 51 febrile neutropenia 51 HbA1c levels 51 NATRECOR R 51 ritonavir boosted 51 pharmacokinetic PK 51 lopinavir r 51 NLX P# 51 VADT 51 NPH insulin 51 candesartan 51 ziprasidone 51 liver metastases 51 reslizumab 51 celecoxib 51 serum phosphorous 51 DAPT 51 #mg BID [003] 51 ibandronate 51 Panzem R NCD 51 HBeAg negative patients 51 anthracycline containing 51 docetaxel 51 QTc prolongation 51 glufosfamide 51 #.#mg/dL 51 nilotinib 51 prespecified secondary 51 APTIVUS r 51 MERLIN TIMI 51 platelet reactivity 51 citalopram 51 CCX# 51 posaconazole 51 AUC0 51 dacarbazine chemotherapy 51 reboxetine 51 BRIM2 51 rosuvastatin #mg 51 GAMMAGARD 51 periprocedural MI 51 mitoxantrone 51 clinically meaningful differences 51 DSMB 51 MoxDuo TM IR 51 definite stent thrombosis 51 advanced adenomas 51 CR nPR 51 enoxaparin 51 aldosterone antagonists 51 pemetrexed 51 salmeterol fluticasone 51 adenoma recurrence 51 SinuNase 51 unblinded 51 BRIM3 51 RG# [001] 51 Cmax 51 phase IIb clinical 51 ramipril 51 preoperative chemotherapy 51 pharmacodynamic 51 urate lowering therapy 51 carotid intima media 51 Ophena 51 ezetimibe 51 VELCADE melphalan 51 systemic absorption 51 BRAF inhibitor 51 canakinumab 51 Secondary endpoints included 51 paricalcitol 51 viral kinetic 51 pharmacodynamic endpoints 51 -#.# mg dL [001] 51 NSABP C 51 plus gemcitabine 51 Fludara 51 telmisartan 51 chlorambucil 51 HbA 1c levels 51 #mg dose [001] 51 pravastatin 51 timepoint 51 Pred Forte 51 Ishak fibrosis score 51 TNF antagonist 51 riociguat 51 sumatriptan naproxen sodium 51 surrogate endpoint 51 Aflibercept 51 P = .# 51 Alzheimer Disease Assessment 51 MYDICAR 51 Subgroup analysis 50 phase IIb 50 tamsulosin 50 CC genotype 50 antiarrhythmic drug 50 postintervention 50 cetuximab 50 FOLFOX6 50 thromboembolic events 50 TRITON TIMI 50 androgen deprivation 50 CANCIDAS 50 Bezielle 50 venlafaxine XR 50 tocilizumab 50 avosentan 50 Darusentan 50 Montgomery Asberg Depression 50 vidofludimus 50 dalteparin 50 unresectable 50 virologic 50 mRCC 50 Montgomery Åsberg Depression 50 Sustained virologic response 50 multivariate Cox 50 adalimumab 50 bortezomib 50 NV1FGF 50 HbA 1c 50 PXD# 50 CCyR 50 voriconazole 50 montelukast 50 Secondary endpoints 50 HGS ETR2 50 orBec 50 zoledronic acid 50 angiographic restenosis 50 HGS ETR1 50 ENDEAVOR IV 50 Primary Endpoint 50 paliperidone ER 50 complete cytogenetic response 50 telbivudine 50 fluticasone salmeterol 50 TAXUS Stent 50 neutrophil counts 50 huC# DM4 50 selenium supplementation 50 eltrombopag 50 AGILECT R 50 Non inferiority 50 glycoprotein IIb IIIa inhibitor 50 mcg dose 50 dacarbazine 50 PREZISTA r 50 paclitaxel carboplatin 50 XmAb# 50 anthracycline taxane 50 solifenacin 50 p = #.# [002] 50 oxcarbazepine 50 enoximone 50 pharmacokinetic parameters 50 clinically meaningful improvement 50 GFT# 50 lamotrigine 50 Perforomist Inhalation Solution 50 LV dysfunction 50 fulvestrant 50 systemically administered 50 fluvastatin 50 ezetimibe simvastatin 50 6MWD 50 renal toxicity 50 certolizumab 50 revascularizations 50 colesevelam HCl 50 EFAPROXYN 50 HCV SPRINT 50 EDEMA3 50 FDA defined valvulopathy 50 TNF blocker therapy 50 analgesic efficacy 50 Pharmacokinetic 50 SIMPADICO 50 log# IU mL 50 plus COPEGUS 50 KRAS mutations occur 50 azathioprine 50 oral antidiabetic medication 50 PRIMO CABG2 50 Traficet EN 50 recurrent GBM 50 NRTI 50 hemoglobin A1c levels 50 mcg albinterferon alfa 2b 50 safinamide 50 reinfarction 50 metformin monotherapy 50 Monotherapy 50 lipid lowering therapy 50 ramelteon 50 risedronate 50 mg qd 50 PEG IFN 50 % Confidence Interval 50 moderate renal impairment 50 Taxotere ® 50 LymphoStat B 50 ELND# 50 statistically significant p 50 CYPHER R Sirolimus eluting 50 axitinib 50 completely resected 50 tenofovir emtricitabine 50 sirolimus stent 50 Phase 2b study 50 infliximab 50 pharmacodynamic parameters 50 PRIMO CABG 50 hypercalcemia 50 sustained virological response 50 mycophenolate mofetil 50 undetectable HBV DNA 50 oral diclofenac 50 heavily pretreated 50 Phase IIB 50 intact parathyroid hormone 50 dose escalation 50 p = NS 50 lipid lowering drugs 50 β blockers 50 oral rivaroxaban 50 chlorthalidone 50 KRN# 50 EGFR TKI 50 glargine 50 tranylcypromine 50 nonfatal MI 50 vicriviroc 50 peg IFN 50 post hoc 50 metastatic castration resistant 50 mcg kg 50 postoperative chemotherapy 50 TOP2A 50 gemcitabine 50 TAXUS p value 50 univariate 50 angiographic outcomes 50 TKM ApoB 50 randomized #:#:# 50 FOLPI 50 rt PA 50 LEXIVA r 50 RLAI 50 MMSE score 50 venous thromboembolism VTE prophylaxis 50 plus MTX 50 EGFR mutation positive 49 annualized relapse 49 proteinuria 49 olmesartan 49 ranibizumab 49 PIX# [002] 49 zolmitriptan 49 rivaroxaban 49 Hematologic 49 pamidronate 49 EGFR mutations 49 DES implantation 49 atorvastatin #mg 49 HAQ DI 49 p = 49 oral ridaforolimus 49 custirsen 49 liver metastasis 49 Rating Scale MADRS 49 idraparinux 49 nelfinavir 49 ustekinumab 49 adjunctive placebo 49 leukopenia 49 Folfox 49 FEV1 49 dosage regimens 49 Scale cognitive subscale 49 pharmacodynamic effects 49 subcutaneous insulin 49 MGd 49 ruboxistaurin 49 log# copies mL 49 K ras mutations 49 ejection fractions 49 pharmacodynamic properties 49 interferon alfa 2a 49 EBRT 49 INCB# [003] 49 NYHA Class II 49 log# reduction 49 darunavir 49 oral FTY# 49 discontinuations due 49 atazanavir 49 repeat revascularization 49 plus methotrexate 49 anemia hemoglobin 49 diuretic chlorthalidone 49 SERCA2a 49 Pegasys ® 49 candesartan cilexetil 49 QTcF 49 experienced virologic failure 49 TORISEL 49 non squamous histology 49 ACE inhibitor ramipril 49 Primary endpoints 49 dexrazoxane 49 intima media thickness 49 AVOREN 49 bendamustine 49 Amrubicin 49 docetaxel pretreated 49 doxorubicin docetaxel 49 univariate analysis 49 stage IIIb IV 49 lipid parameters 49 nmol liter 49 gp# vaccine 49 ACCORD Lipid 49 zalutumumab 49 revascularization procedures 49 pharmacodynamics PD 49 #mg doses [002] 49 achieved CCyR 49 ribavirin therapy 49 AVADO 49 Bonferroni correction 49 generalizability 49 thienopyridines 49 NYHA class 49 dose regimens 49 TACE 49 multivariable analysis 49 F FDG PET 49 lacosamide 49 DLTs 49 ADCS CGIC 49 imetelstat 49 interferon ribavirin 49 selective modulator 49 recurrent ischemia 49 ataluren 49 imatinib 49 aminotransferases 49 placebo dexamethasone 49 IV bisphosphonates 49 LATUDA 49 enalapril 49 mcg mL 49 Peg IFN 49 dose proportionality 49 dosing cohort 49 HOMA IR 49 ACTEMRA 49 ACR# response 49 seliciclib 49 sUA 49 mg p = 49 Median PFS 49 rabeprazole 49 PREZISTA r arm 49 delafloxacin 49 locoregional 49 SPIRIT FIRST 49 mg doses 49 FluCAM 49 arterial thromboembolic events 49 MAP# 49 Phase 2a trial 49 esomeprazole 49 zotarolimus eluting stent 49 placebo controlled studies 49 ARCOXIA 49 HIV RNA 49 lymph node involvement 49 mg ustekinumab 49 plasma uric acid 49 PegIntron 49 phase Ib 49 mcg BID 49 randomized discontinuation trial 49 urinary N telopeptide 49 MEND CABG II 49 #mg/day [002] 49 rBChE 49 placebo controlled trials 49 ADAGIO study 49 darusentan 49 cobicistat 49 virologically 49 DAS# remission 49 mTOR inhibitors 49 rHuEPO 49 icatibant 49 mg QD 49 PEGylated anti 49 relapsed SCLC 49 Secondary efficacy endpoints 49 oral antidiabetic agents 49 adjuvant therapy 49 substudy 49 QT QTc 49 stage IIIB 49 clinicopathological features 49 Zevalin consolidation 49 benazepril 49 TAXUS Express Stent 49 ABSORB trial 49 LV ejection fraction 49 -#.# log# copies mL 49 edoxaban 49 VEGF inhibitors 49 catheter occlusion 49 budesonide 49 COPEGUS 49 entecavir 49 rALLy trial 49 -#.# log# 49 exemestane 49 PROMACTA 49 TAXUS stent 49 GRNCM1 49 hip BMD 48 dapagliflozin plus 48 evaluable 48 acute bronchospasm 48 oblimersen 48 systolic dysfunction 48 Xinlay 48 monotherapy 48 REYATAZ r 48 baminercept 48 lipid lowering medications 48 multivariate adjustment 48 TIMI 48 liposomal amphotericin B 48 echocardiographic parameters 48 plasma pharmacokinetics 48 rizatriptan 48 lamivudine 48 tanespimycin 48 serum phosphorus 48 atrasentan 48 olanzapine 48 liver histology 48 celgosivir 48 denufosol 48 EchoCRT 48 rimonabant #mg 48 amprenavir 48 null responders 48 lumbar spine bone 48 prospective multicenter randomized 48 indinavir 48 ADHD RS 48 Atacand 48 acutely decompensated congestive heart 48 estramustine 48 docetaxel Taxotere ® 48 prospective randomized controlled 48 TIMP 1 48 EURIDIS 48 GOUT 48 Baseline characteristics 48 PCI ExTRACT TIMI 48 satraplatin Phase 48 Negative Syndrome 48 haematologic 48 microbiological eradication 48 standard chemotherapy regimen 48 NYHA functional class 48 reintervention 48 panitumumab 48 advanced adenoma 48 Lucentis monotherapy 48 cerebrovascular events 48 S/GSK# 48 flutamide 48 pomalidomide 48 eribulin 48 insulin lispro 48 pg ml 48 fluticasone 48 ULORIC 48 biphasic insulin aspart 48 darunavir ritonavir 48 myocardial infarctions 48 intravenous cyclophosphamide 48 NEVO 48 hemoglobin A1c HbA1c 48 symptomatic VTE 48 donepezil 48 #mg BID [002] 48 1mg dose 48 Cleviprex TM clevidipine 48 #ng/ml 48 FOLFOX4 alone 48 μmol L 48 tumor histology 48 low dose cytarabine 48 phonophobia 48 laboratory abnormalities 48 8mg/kg 48 Flu Cy 48 recurrent glioblastoma multiforme 48 melphalan prednisone 48 coadministration 48 P ≤ 48 TAXUS ATLAS 48 CombAT 48 caspofungin 48 sitagliptin 48 pegylated liposomal doxorubicin 48 diameter stenosis 48 antiplatelet agent 48 somatostatin analog 48 linaclotide treated 48 SABCS 48 gadobutrol 48 rosuvastatin 48 dosing cohorts 48 XIENCE V vs. 48 multicenter randomized controlled 48 otamixaban 48 Androxal TM 48 QRS duration 48 aprepitant 48 ertapenem 48 mirtazapine 48 PFO migraine 48 Dextofisopam 48 KRAS mutant tumors 48 rhGH 48 T#I [002] 48 coadministered 48 undetectable HCV RNA 48 p = #.# [004] 48 VaD 48 tumor progression TTP 48 multivariable adjusted 48 Omnitarg 48 iclaprim 48 ug dose 48 recurrent VTE 48 pegylated interferon alpha 48 CRp 48 free survival PFS 48 tumor shrinkage 48 seroprotection 48 anti leukemic 48 mmHg p = 48 nondiabetic patients 48 rilpivirine 48 metastatic RCC 48 randomized Phase III 48 receiving golimumab 48 aripiprazole 48 AUA Symptom Score 48 HbA 1C 48 μg kg 48 SGRQ 48 pharmacodynamic PD 48 ONTARGET 48 corrected QT interval 48 rFVIIa 48 metaglidasen 48 SCIg 48 Recentin 48 dobutamine 48 NIHSS score 48 D#A [002] 48 stent binary restenosis 48 atheroma volume 48 pulmonary exacerbations 48 demonstrated clinically meaningful 48 perioperative complications 48 teriparatide 48 relapsed myeloma 48 HER2 expression 48 neostigmine 48 Xcytrin 48 dose dexamethasone 48 beta blocker therapy 48 HbA1c 48 double blinded placebo 48 KRAS mutation 48 LB# [003] 48 p = .# [002] 48 pain palliation 48 YERVOY 48 PREMPRO 48 fosamprenavir 48 mmol kg 48 ancrod 48 valacyclovir 48 titrated glipizide 48 HMG CoA reductase inhibitors 48 lopinavir ritonavir 48 amiodarone 48 d4T 48 ProSavin 48 reoperation 48 leukocyte count 48 dutasteride 48 infliximab monotherapy 48 salmeterol HFA MDI 48 antihypertensive medications 48 tenecteplase 48 tolterodine ER 48 crizotinib PF # 48 prior chemotherapy regimens 48 miconazole 48 carotid IMT 48 PROactive study 48 SPIRIT III 48 MDRD 48 steroid dexamethasone 48 NAbs 48 daclizumab 48 null hypothesis 48 CYPHER Stent 48 left ventricular ejection 48 administered subcutaneously 48 INC# 48 AVERROES 48 iloprost 48 TEAEs 48 A1c levels 47 MIST II 47 HBeAg seroconversion 47 micafungin 47 interobserver reliability 47 surrogate markers 47 Left Ventricular Ejection Fraction 47 aliskiren 47 Hazard Ratio HR 47 serum calcium 47 treat NNT 47 Viread Emtriva 47 dexamethasone Decadron 47 ANCHOR trial 47 hematologic toxicity 47 pentoxifylline 47 ARCALYST ® 47 mucosal healing 47 Hazard Ratio 47 docetaxel chemotherapy 47 ASTEROID 47 p = #.# [003] 47 phase IIIb 47 atazanavir ritonavir 47 statistically significant correlations 47 prednisone prednisolone plus 47 cannabinor 47 nadroparin 47 Trofex 47 sitaxsentan 47 refractory NSCLC 47 diabetic neuropathic pain 47 DOXIL 47 VcMP 47 Maximum Tolerated Dose 47 concomitant medications 47 achieving PASI 47 APTIVUS 47 evaluating REVLIMID 47 RE LY ® 47 cobiprostone 47 KRAS mutations 47 salmeterol 47 tolerability 47 pyridostigmine 47 Virulizin ® 47 stent thromboses 47 Unified Parkinson Disease 47 methotrexate therapy 47 EUS FNA 47 severe neutropenia 47 postdose 47 DAVANAT 47 eculizumab 47 Telcyta 47 peginesatide 47 neoadjuvant chemotherapy 47 beclomethasone dipropionate 47 losartan 47 M6G 47 multicentre randomized 47 microbiologically evaluable 47 plus medroxyprogesterone acetate 47 KRAS wild 47 velafermin 47 medically inoperable 47 placebo fluoxetine 47 triamcinolone 47 fluorouracil 47 TRIOLEX 47 rEEG 47 troponin T 47 enfuvirtide 47 clevidipine 47 HIV HCV coinfected 47 chemoradiation therapy 47 segment binary restenosis 47 ONGLYZA 47 efficacy 47 dose limiting toxicities 47 irinotecan cisplatin 47 mg BID dose 47 prospectively stratified 47 NIHSS 47 lanthanum carbonate 47 talactoferrin 47 MEND CABG 47 thrombotic events 47 clinically evaluable 47 adalimumab Humira 47 ILLUMINATE 47 dexpramipexole 47 Randomized Evaluation 47 nadolol 47 squamous histology 47 comparator PI r 47 ATV RTV 47 antiarrhythmic 47 clopidogrel 47 EVEREST II 47 oral allopurinol 47 BARACLUDE r 47 prostate cancer CRPC 47 VAPRISOL 47 mg/m2 dose 47 Ranolazine 47 HuMax EGFr 47 carotid plaque 47 graft occlusion 47 Stage IIIb 47 Thrombolysis 47 hyperoxaluria 47 p ≤ 47 RSD# oral 47 divalproex 47 sipuleucel T 47 IR prednisone 47 temsirolimus 47 symptomatic intracerebral hemorrhage 47 mITT population